Boston Hospitals To Test Cystic Fibrosis Drug On Severely Ill Coronavirus Patients

BOSTON (CBS) — Harvard University researchers are working with two Boston hospitals to try a new way to help the sickest coronavirus patients. Boston Children’s Hospital and Brigham and Women’s Hospital will test a drug approved by the FDA to treat people with cystic fibrosis on those experiencing severe COVID-19 pneumonia and respiratory failure. The drug is called Dornase alfa, also known as DNase 1 or Pulmozyme, and it works to prevent lung infections by breaking up thick mucus. That may make oxygen easier to deliver via ventilator, researchers say. There’s also hope that the drug might break up neutrophil extracellular traps or NETs, which the researchers say could be contributing to lung inflammation. A neutrophil, blue, releases unwound DNA, the backbone of NETs. The dots show proteins modified during NET formation or released by neutrophils and bound to NETs. Image credit: Lucas de Meglio and Patrick Munzer/Boston Children’s “We hope this drug, which is known to be safe, will help reduce the inflammation that contributes to worsening respiratory distress in COVID-19,” said the study’s lead investigator, Benjamin Raby, who is a Harvard Medical School professor and chief of pulmonary medicine at Children’s. The goal of the 18-month randomized, controlled study is to find out how many patients are alive and off a ventilator after 28 days. It aims to enroll 60 adults and children who need mechanical ventilation.   ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston Syndicated Local Boston Children's Hospital Brigham and Women's Hospital Coronavirus Harvard University Source Type: news

Related Links:

Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Source: Academic Radiology - Category: Radiology Source Type: research
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
Source: Personality and Individual Differences - Category: Psychiatry & Psychology Source Type: research
AbstractObjectivesSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and recruitment of neutrophils in the lungs. Activated neutrophils induce inflammation and severe alveolar injury by releasing neutrophil extracellular traps (NETs). The backbones of many DAMPs and NETs are made of extracellular, cell-free DNA decorated with highly toxic compounds such as elastase, myeloperoxidase and citrullinated histones. Dornase alfa is a FDA-approved recombinant human DNAse 1 for th...
Source: Trials - Category: Research Source Type: clinical trials
She had trouble breathing, and the E.R. doctors discovered a mass in her lung. Was this cancer — or something a little more unusual?
Source: NYT Health - Category: Consumer Health News Authors: Tags: Cystic Fibrosis Coronavirus (2019-nCoV) Senses and Sensation Lungs Hospitals Pneumonia Smoking and Tobacco Source Type: news
A cluster of cases of pneumonia of unknown origin presented in Wuhan, China in early December 2019; the cause was subsequently found to be a novel coronavirus, now named SARS-Cov-2 [1]. This new virus is highly transmissible and has resulted in a pandemic with over 2 million confirmed infections and more than 145,000 deaths in humans in 185 countries [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Source Type: research
More News: Children | Coronavirus | COVID-19 | Cystic Fibrosis | Harvard | Health | Hospitals | Pneumonia | Pulmozyme | Respiratory Medicine | Sports Medicine | Study | Women